Astellas Pharma (4503.T) Financial Analysis & Valuation | Quarter Chart
Astellas Pharma (4503.T)
4503.TPrice: $14.82
Fair Value: 🔒
🔒score
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 m... more
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals wo... more
Description
Shares
| Market Cap | $26.55B | Exchange | JPX |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | JP | CEO | Naoki Okamura |
| IPO Date | 2000-01-04 | CAGR | 0.06% |
| Employees | 14,754 | Website | www.astellas.com |
| Div. Yield | 0.01% | Payout Ratio | 1.62% |
| Buy Back Yield | 0.01% | Total Yield | 0.02% |
4503.T chart loading...
Fundamentals
Technicals
| Enterprise Value | $3224.64B | P/E Ratio | 34.03 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 53800410648.21 | P/B Ratio | 70703680224.3 |
| P/CF Ratio | 436294033523.07 | P/FCF Ratio | 510985407782.38 |
| EPS | $0.44 | EPS Growth 1Y | 354.11% |
| EPS Growth 3Y | -29.12% | EPS Growth 5Y | -54.62% |
| Revenue Growth 1Y | 14.29% | Gross Margin | 0.78% |
| Operating Margin | 0.15% | Profit Margin | 0.04% |
| ROE | 0.05% | ROA | 0.02% |
| ROCE | 0.13% | Current Ratio | 1.17 |
| Quick Ratio | 0.89 | Cash Ratio | 0.19 |
| Debt/Equity | 0.6 | Interest Coverage | 15.57 |
| Altman Z Score | 2.21 | Piotroski Score | 8 |